BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS

被引：1
|
作者：
Fortune-Greeley, A. [1 ]
Cornell, P. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72147-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A34 / A34
页数：1
相关论文
共 50 条
  • [1] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K. W.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher R.
    Hall, Peter S.
    [J]. ONCOLOGIST, 2017, 22 (06): : 694 - 699
  • [2] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [3] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [4] Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer
    Refaat, Tamer
    Choi, Mehee
    Gaber, Germaine
    Kiel, Krystyna
    Mehta, Minesh
    Gradishar, William
    Small, William, Jr.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05): : 480 - 485
  • [5] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
    Barrington, David A.
    Riedinger, Courtney
    Haight, Paulina J.
    Tubbs, Crystal
    Cohn, David E.
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 500 - 505
  • [7] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
    Sherman, Scott K.
    Lange, Joel J.
    Dahdaleh, Fadi S.
    Rajeev, Rahul
    Gamblin, T. Clark
    Polite, Blase N.
    Turaga, Kiran K.
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
  • [9] Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
    Dai, Wei Fang
    Beca, Jaclyn M.
    Nagamuthu, Chenthila
    Liu, Ning
    de Oliveira, Claire
    Earle, Craig C.
    Trudeau, Maureen
    Chan, Kelvin K. W.
    [J]. JAMA ONCOLOGY, 2022, 8 (04) : 597 - 606
  • [10] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
12345